1. Pink Sheet
  2. >>Market Access

Drug Cost Blame Game: Payers’ Contribution To Prices Getting More Attention

 
• By Cathy Kelly

Lawsuit accuses UnitedHealth of elevating member copays in order to recoup the spread between cost sharing and the amount pharmacies pay for a drug.

RollOfDollarswithPills_1200x675

In the ongoing public debate about high prescription drug costs, insurers and pharmacy benefit managers are facing increasing levels of scrutiny for their contribution to the growing burden on patients.

The development could take some heat off manufacturers, which have been the main focus of public criticism over increasing drug...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Access

More from Pink Sheet

Recent And Upcoming FDA Advisory Committee Meetings

 
• By Sue Sutter

Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.

UK-Wide Strategy Needed To Move Clinical Trial Diversity Plans To Next Stage

 
• By Vibha Sharma

The UK’s research-based pharma industry and medical research charities have set out clear action points to drive greater diversity and inclusion in clinical trials.

Blenrep’s Comeback Continues As England Becomes First To Fund Drug

 
• By Eliza Slawther

Blenrep, GSK’s multiple myeloma therapy, faced a major setback when it was withdrawn from the market in 2022. The drug has since made a return as a second-line therapy, and is on track to being reimbursed in England.